TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02656108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ommited controlled cord traction
Description: No controlled cord traction and no fundal pressure. placenta will be allowed to deliver physiologically

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: controlled cord traction
Description: active management of third stage of labor in the form of uterine massage with controlled cord traction
Study: NCT01733914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture in the following acupoints on the contralateral side of pain site: Jiantong, Zhongzhu, Houxi, and Quchi. The patient will receive 5 treatments (each lasts 30 min) per week for four weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Patients in the waiting list group received conventional orthopaedic therapy including physical exercise, heat or cold therapy. 50 mg diclofenac daily could be taken when the patient suffered from the pain. Injections or cortisone applications of any kind were not allowed.
Study: NCT02857686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: forearm IVRA
Description: tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
Study: NCT02020200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPH
Description: MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight\<40 kg; 30 mg in case weight\>90 kg; otherwise 20 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00865033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCL Tablets, 1000 mg Sandoz

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage 1000 mg
Study: NCT01262872

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-Vac™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-Vac™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-Vac™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stamaril™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stamaril™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stamaril™
Description: Intramuscular injection
Study: NCT01599078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Drug dosing is 3mcg/mm3 of artery treated with percutaneous revascularization. Drug will be administered via the TAPAS catheter and allowed to dwell for 5 minutes.
Study: NCT02500953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01835158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01849211

Intervention type: DRUG
Group type: OTHER
Intervention: rocuronium
Study: NCT02037425

Intervention type: DRUG
Group type: OTHER
Intervention: onabotulinumtoxinA
Description: BOTOX® (Formulation Number 9060X) contains 200 International Units (IU) of Clostridium botulinum Toxin Type A, reconstituted with 4 cc of normal saline providing 5 units per 0.1 cc. At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
Study: NCT01599078

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be administered intra-arterially via the TAPAS catheter following percutaneous revascularization. The dwell time will be 5minutes.
Study: NCT04111991

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care in the NCH in the Complex Concussion Clinic involves assessment and treatment with a neurologist for medical management of concussion, weekly sessions with an athletic trainer for exercise therapy, and physical therapy sessions depending on need

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care in the NCH in the Complex Concussion Clinic involves assessment and treatment with a neurologist for medical management of concussion, weekly sessions with an athletic trainer for exercise therapy, and physical therapy sessions depending on need

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C-STEP (Cognitive Behavioral Therapy)
Description: The C-STEP intervention involves 4 primary components: psychoeducation, activity management, sleep hygiene, and relaxation training
Study: NCT00402675

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Timing of percutaneous coronary intervention
Description: Immediate, early or selective invasive angiography
Study: NCT02226237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: group of pelvic floor exercises
Description: contraction of the pelvic floor muscles sustained for 5 seconds, hip adductors using pillow and elevation of the hip, 30 repetitions of each exercise
Study: NCT01225250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polydioxanone (PDS) plates
Description: 0.5 mm PDS Flexible Plate made of poly-p-dioxanone, an aliphatic polyester which is manufactured by polymerization of the monomer p-dioxanone. Polydioxanone is a resorbable material degraded by hydrolysis and has been successfully used for bone discontinuities and septal reconstruction.
Study: NCT00402675

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Timing of percutaneous coronary intervention
Description: Immediate, early or selective invasive angiography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Timing of percutaneous coronary intervention
Description: Immediate, early or selective invasive angiography
Study: NCT02226237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: group of pelvic floor exercises
Description: contraction of the pelvic floor muscles sustained for 5 seconds, hip adductors using pillow and elevation of the hip, 30 repetitions of each exercise

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anal electrostimulation group
Description: The anal electrical stimulation protocol was performed by a physical therapist for seven weeks, twice per week, using the apparatus Dualpex 961 Uro® Quark, with frequency of 35 Hz, and the intensity determined according to the tolerance of the patient, lasting 20 minutes.
Study: NCT01225250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal septal extension graft performed through endonasal rhinoplasty
Description: The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Caudal septal extension graft performed through endonasal rhinoplasty
Description: The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
Study: NCT01841684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Description: 100 mg tablet orally, once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for anacetrapib orally, once daily for 12 weeks
Study: NCT00197444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDGP/5-FU combined with radiation
Description: Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Fractionated external radiotherapy was performed from the first day of chemotherapy and a total dose of 50.4-66 Gy was delivered at the rate of 1.8-2.0 Gy per fraction.
Study: NCT05147207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superpath Approach
Description: This is a minimally invasive surgical approach for THA.
Study: NCT03622580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.
Study: NCT02793557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOL-005
Description: Intradermal injection of 50 μl solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOL-005
Description: Intradermal injection of 50 μl solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOL-005
Description: Intradermal injection of 50 μl solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOL-005
Description: Intradermal injection of 50 μl solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06037577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM-101
Description: Anti-human CCL24 monoclonal antibody (CM-101)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT00033748

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody 11D10 anti-idiotype
Description: 2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody 3H1 Alu Gel
Description: 2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
Study: NCT04582851

Intervention type: OTHER
Intervention: some risk factors correlated with TMD
Description: exposure factors causing TMD
Study: NCT00002524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride (DOX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride (DOX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentamidine
Study: NCT01835158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT00584519

Intervention type: OTHER
Intervention: non-interventional
Description: non-interventional
Study: NCT02655549

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Px563L, RPA563, or placebo
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Px563L, RPA563, or placebo
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Px563L, RPA563, or placebo
Description: Two intramuscular injections
Study: NCT02542826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Patients will participate in 3 exercise training sessions/wk for a period of 7-12 wks at one of 4 sites in Quebec. Each training session will include 30-45 min of aerobic training (cycling and/or treadmill walking) at a target intensity of 80% of the maximal heart rate achieved during a symptom-limited incremental cycle exercise test performed prior to the pulmonary rehabilitation program; and 20-30 min of strength training exercises.
Study: NCT01383226

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Thoracic endosonography
Description: Thoracic endosonography is a minimal invasive diagnostic intervention
Study: NCT03016065

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea Fiber
Description: Baked goods (2 snacks) with fiber-fortified with 5 g/snack of ground pea hulls

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Baked goods (2 snacks) without added fiber
Study: NCT02037334

Intervention type: DEVICE
Intervention: Pregnolia System
Description: No intervention is done except for measuring the stiffness of the cervix in pregnant women
Study: NCT00837070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous zygapophyseal cyst rupture
Description: Patients will be treated by introducing a 20G spinal needle in the inferior joint recess of the zygapophyseal joint.1 ml of celestone-chronodose,1 ml of Marcain 5 mg/ml and 1-3 ml of contrast media:Omnipaque 240 will be injected until the cyst ruptures.
Study: NCT00653588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 80mg
Study: NCT01987440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lubricating gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lubricating gel
Study: NCT00626353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Description: Rehabilitation at home during hospital stay and after discharge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care during hospital stay and in the municipality after discharge
Study: NCT03143790

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Terapy
Description: Intervention is treatment with ESWT. Placebo treatment is using the same device as the active treatment, but the shock waves stopped in a non pressure-conductive filter
Study: NCT00002524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentamidine
Study: NCT03143790

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Extracorporeal Shockwave Terapy
Description: Intervention is treatment with ESWT. Placebo treatment is using the same device as the active treatment, but the shock waves stopped in a non pressure-conductive filter
Study: NCT04257500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel/ethinyl estradiol vaginal ring
Description: 16 weeks of continuous use of contraceptive vaginal ring
Study: NCT03773432

Intervention type: OTHER
Group type: OTHER
Intervention: Probe meal
Description: The probe meal will be administered either in the afternoon (conventional schedule) or in the morning (unconventional schedule).

Intervention type: OTHER
Group type: OTHER
Intervention: Probe meal
Description: The probe meal will be administered either in the afternoon (conventional schedule) or in the morning (unconventional schedule).
Study: NCT02386085

Intervention type: PROCEDURE
Intervention: Osteopathic manipulative treatment (OMT)
Description: OMT will be provided as part of the patient's health care, prior to enrollment in the study. All participants would have received the same intervention (OMT) if they had not enrolled in the study.
Study: NCT02049684

Intervention type: PROCEDURE
Intervention: Patch
Study: NCT01557439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine Dihydrochloride 5 mg Tablets
Description: A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine Dihydrochloride 5 mg Tablets
Description: A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets
Study: NCT01255709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm T1: Primatene Mist HFA
Description: epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
Study: NCT00931411

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formulation 609580 20
Description: Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formulation 609580 20
Description: Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
Study: NCT00931411

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formulation 609209 (Lipikar Baume)
Description: Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formulation 609209 (Lipikar Baume)
Description: Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
Study: NCT04610905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing sedentary behaviour
Description: This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours. The participants will receive a diary to write down whether they stand up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase physical activity
Description: This group will be asked to be more physically active. They need to be active during 150min/week. It can include walking, to ride a bike, jogging, tennis, football,... Additionnaly they need to be active in periods of at least 10 minutes. The participants will receive a diary to write down which activity they did and also for how long.
Study: NCT01255709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm T2: Primatene Mist HFA
Description: epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
Study: NCT02101125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study: NCT00002524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-Sulfamethoxazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-Sulfamethoxazole
Study: NCT01255709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)
Description: epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
Study: NCT00629993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Detailing
Description: It will involve multiple intervention components, some of which are standardized across physicians (i.e., self learning packets, post-tests for CME credit, CD-ROMS, videos, newsletters, culturally sensitive patient education materials, office staff informational sessions, chart and patient reminders, and a general office routine for cervical cancer counseling, including performance feedback, as well as media-ready materials). Academic detailing and the specific office routines will be customized to each physician, although the frequency of the detailing visits will be routinized across all participants, to reduce cost and to maximize its potential for dissemination.
Study: NCT02635698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optifast
Description: medically-supervised weight management program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food-Based
Description: low-energy, low-fat diet